BRIEF-Protagonist Therapeutics says will be responsible for conduct of Phase 1 clinical trial for PTG-200
May 30, 2017 at 07:40 AM EDT
* Protagonist Therapeutics Inc says co will be responsible, at its own expense, for conduct of Phase 1 clinical trial for PTG-200 - SEC filing